• DRAMP ID

    • DRAMP29200
    • Peptide Name

    • EK1-GSGSGC
    • Source

    • Synthetic construct
    • Family

    • Belongs to the betacoronaviruses spike protein family.
    • Gene

    • S
    • Sequence

    • SLDQINVTFLDLEYEMKKLEEAIKKLEESYIDLKELGSGSGC
    • Sequence Length

    • 42
    • Protein Existence

    • Hemology
    • SMILES

    • CC[C@@H](C)[C@H](NC(=O)CC[C@H](NC(=O)[C@H](CCCCN)NC(=O)CC[C@H](NC(=O)[C@H](CCC(=O)N[C@@H](CCSC)C(=O)O)NC(=O)[C@H](CC(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)O)[C@@H](C)O)[C@H](C)CC)C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(=O)N[C@@H](CCC(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)O)C(=O)NCC(=O)NCC(=O)NCC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)O)[C@H](C)CC
    • Biological Activity

    • Antimicrobial, Antiviral(SARS-CoV-2)
    • Target Organism

      • [Ref.33082259]Virus:
      • SARS-CoV-2:
        Target OrganismActivity
        ihibition of cell-cell fusion in 293T cellsIC50=293±60 nM,IC90>900 nM
        inhibition of infection in Vero E6 cellsIC50~ 41 nM
      • SARS-CoV-2_D614G:
        Target OrganismActivity
        ihibition of cell-cell fusion in 293T cellsIC50=261±136 nM,IC90=892±100 nM
      • SARS-CoV-2_S943P:
        Target OrganismActivity
        ihibition of cell-cell fusion in 293T cellsIC50=286±104 nM,IC90>1000 nM
      • SARS-CoV-2_S247R:
        Target OrganismActivity
        ihibition of cell-cell fusion in 293T cellsIC50=194±107 nM,IC90=893±77 nM
      • MERS-CoV:
        Target OrganismActivity
        ihibition of cell-cell fusion in 293T cellsIC50>1000 nM,IC90>1000 nM
        inhibition of infection in Vero E6 cellsIC50~ 2 nM
      • SARS-CoV-1:
        Target OrganismActivity
        ihibition of cell-cell fusion in 293T cellsIC50=36±5 nM,IC90>1000 nM
    • Hemolytic Activity

      • No hemolysis information or data found in the reference(s) presented in this entry
    • Cytotoxicity

      • [Ref.33082259]Human embryonic kidney HEK293T cells:<5% Cytotoxicity at 10 µM;Vero E6 cells:18% Cytotoxicity at 10 µM.
    • Binding Target

    • liposomes
    • Linear/Cyclic

    • Linear
    • N-terminal Modification

    • Free
    • C-terminal Modification

    • Free
    • Nonterminal Modifications and Unusual Amino Acids

    • None
    • Stereochemistry

    • L
    • Structure

    • Not found
    • Structure Description

    • Not found
    • PDB ID

    • None
    • Predicted Structure

    • Formula

    • C211H341N49O72S2
    • Absent Amino Acids

    • HPRW
    • Common Amino Acids

    • EL
    • Mass

    • 4780.43
    • PI

    • 4.36
    • Basic Residues

    • 5
    • Acidic Residues

    • 10
    • Hydrophobic Residues

    • 13
    • Net Charge

    • -5
    • Boman Index

    • -6573
    • Hydrophobicity

    • -0.379
    • Aliphatic Index

    • 102.14
    • Half Life

      • Mammalian:1.9 hour
      • Yeast:>20 hour
      • E.coli:>10 hour
    • Extinction Coefficient Cystines

    • 2980
    • Absorbance 280nm

    • 72.68
    • Polar Residues

    • 12

DRAMP29200

    • Mechanism of action

    • The lipopeptide is derived from the C-terminal heptad repeat (HRC) domain of SARS-CoV-2 S that potently inhibits infection by SARS-CoV-2.
  • ·Literature 1
    • Title

    • Inhibition of Coronavirus Entry In Vitro and Ex Vivo by a Lipid-Conjugated Peptide Derived from the SARS-CoV-2 Spike Glycoprotein HRC Domain.
    • Reference

    • mBio. 2020 Oct 20;11(5):e01935-20.
    • Author

    • Outlaw VK, Bovier FT, Mears MC, Cajimat MN, Zhu Y, Lin MJ, Addetia A, Lieberman NAP, Peddu V, Xie X, Shi PY, Greninger AL, Gellman SH, Bente DA, Moscona A, Porotto M.